Market Overview

'Horrible': JPMorgan Chase Receives Pushback On Biotech Conference Restrictions

Share:
'Horrible': JPMorgan Chase Receives Pushback On Biotech Conference Restrictions

JPMorgan Chase & Co. (NYSE: JPM) is taking heat from investors, reporters and biotech enthusiasts this week after the company decided to restrict access to its small breakout sessions following presentations at its upcoming 36th Annual Healthcare Conference in San Francisco Jan. 8-11.

“Company presentations are on-the-record. Press are permitted in the company presentations, however press is NOT permitted in the small breakouts that immediately follow the presentations nor on the 1x1 floors,” JPMorgan said in a notice to reporters. According to STAT News’ Adam Feuerstein, this is the first time in 16 conferences he’s attended at the same venue that press has been banned from breakout discussions.

Other conference attendees took to Twitter to voice their opposition to the decision as well. A spokesperson for JPMorgan reportedly said the new rule was about space, not access to information.

Michael Gilman, founder and CEO of Arrakis Therapeutics, said the decision is thinly veiled political elitism.

Investor Brad Loncar said it’s ridiculous that investors don’t have access to these critical presentations and called for JPMorgan to live stream all the Q&A sessions via webcast.

Others, such as Endpoints News co-founder John Carroll, criticized the event for its cold treatment of attendees.

Investors, members of the press and the biotech community have taken to social media using the hashtag #JPM18 to protest the press ban at the conference.

Related Links:

ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More 

11 Biotech Stocks Moving From ASH 2017

A staircase at the Westin St. Francis in San Francisco, the location of the JPMorgan Healthcare Conference. Photo from Pixabay. 

Posted-In: Adam FeuersteinBiotech News Health Care Events Top Stories Media General Best of Benzinga

 

Related Articles (IBB + JPM)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Mid-Afternoon Market Update: LiNiu Technology Surges Following 1H'17 Results; Ekso Bionics Shares Slide

Kim And Kanye's 2018 Stock Playbook